Justin Chickles

Justin Chickles is the CEO and co-founder of Glycyx Therapeutics, a clinical-stage biotech company tackling a hidden cause of immunotherapy failure in cancer patients: opioids. With a background leading ventures across therapeutics, diagnostics, and digital health, Justin has spent the last four years advancing axelopran, a first-in-class therapy designed to reverse opioid-induced immunodeficiency. Under his leadership, Glycyx has progressed from scientific insight to a Phase 2 human trial launching this fall. Prior to Glycyx, he held executive roles at Johnson & Johnson and multiple venture-backed startups.